Drugs / Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells
Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02418325 | Feb 2015 → Feb 2017 | relapsing-remitting multiple sclerosis | Genesis Limited | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT02587715 | Feb 2015 → Feb 2017 | relapsing-remitting multiple sclerosis | Novo Cellular Medicine Institute LLP | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02418325 ↗ |
| Known as | UC-MSC | “Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of...” NCT02418325 ↗1“Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of...” NCT02587715 ↗ |
| Known as | UC-MSCs | “Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of...” NCT02587715 ↗1“Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of...” NCT02418325 ↗ |
| Modality | Cell therapy | “The proposed study will assess safety and primary and secondary efficacy endpoints after super selective intravenous and intrathecal administration of allogeneic umbilical cord...” NCT02418325 ↗ |
| Route | Intravenous | “Super selective intravenous administration” NCT02418325 ↗ |